Questar Asset Management Inc. Purchases Shares of 3,091 Abbott Laboratories (ABT)

Questar Asset Management Inc. acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,091 shares of the healthcare product maker’s stock, valued at approximately $224,000.

A number of other large investors also recently added to or reduced their stakes in ABT. Vanguard Group Inc. boosted its position in Abbott Laboratories by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 139,012,321 shares of the healthcare product maker’s stock worth $10,197,944,000 after acquiring an additional 2,208,781 shares during the period. Vanguard Group Inc boosted its position in Abbott Laboratories by 1.6% during the 3rd quarter. Vanguard Group Inc now owns 139,012,321 shares of the healthcare product maker’s stock worth $10,197,944,000 after acquiring an additional 2,208,781 shares during the period. BlackRock Inc. boosted its position in Abbott Laboratories by 0.9% during the 3rd quarter. BlackRock Inc. now owns 117,203,489 shares of the healthcare product maker’s stock worth $8,598,048,000 after acquiring an additional 1,053,749 shares during the period. Bank of New York Mellon Corp boosted its position in Abbott Laboratories by 102,159.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 27,234,758 shares of the healthcare product maker’s stock worth $1,997,943,000 after acquiring an additional 27,208,125 shares during the period. Finally, Morgan Stanley boosted its position in Abbott Laboratories by 7.3% during the 3rd quarter. Morgan Stanley now owns 22,766,174 shares of the healthcare product maker’s stock worth $1,670,126,000 after acquiring an additional 1,547,898 shares during the period. Institutional investors and hedge funds own 72.57% of the company’s stock.

A number of brokerages have issued reports on ABT. Argus boosted their price target on Abbott Laboratories to $90.00 and gave the stock an “in-line” rating in a research report on Friday, January 25th. They noted that the move was a valuation call. Gabelli reiterated a “buy” rating on shares of Abbott Laboratories in a research report on Wednesday, January 2nd. Goldman Sachs Group upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and set a $74.10 price target for the company in a research report on Sunday, December 9th. UBS Group began coverage on Abbott Laboratories in a research report on Tuesday, November 27th. They set a “buy” rating and a $83.00 price target for the company. Finally, Morgan Stanley boosted their price target on Abbott Laboratories from $80.00 to $82.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $79.48.

Shares of Abbott Laboratories stock opened at $75.14 on Friday. The company has a quick ratio of 1.13, a current ratio of 1.42 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $132.67 billion, a PE ratio of 26.09, a PEG ratio of 2.01 and a beta of 1.14. Abbott Laboratories has a fifty-two week low of $56.81 and a fifty-two week high of $75.57.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, January 23rd. The healthcare product maker reported $0.81 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.81. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.82 billion. Abbott Laboratories had a return on equity of 16.50% and a net margin of 7.74%. The company’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.74 earnings per share. Equities analysts anticipate that Abbott Laboratories will post 3.2 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, February 15th. Stockholders of record on Tuesday, January 15th were issued a $0.32 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.28. The ex-dividend date was Monday, January 14th. This represents a $1.28 annualized dividend and a dividend yield of 1.70%. Abbott Laboratories’s dividend payout ratio is 44.44%.

In other news, Director John G. Stratton acquired 3,455 shares of the business’s stock in a transaction dated Thursday, January 31st. The stock was acquired at an average price of $72.32 per share, for a total transaction of $249,865.60. Following the completion of the acquisition, the director now directly owns 3,558 shares in the company, valued at approximately $257,314.56. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link . Also, Chairman Miles D. White sold 142,341 shares of the company’s stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $72.35, for a total value of $10,298,371.35. Following the completion of the sale, the chairman now owns 3,459,185 shares of the company’s stock, valued at approximately $250,272,034.75. The disclosure for this sale can be found here . Corporate insiders own 0.74% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Further Reading: What is the Stochastic Momentum Index (SMI)? Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT) Receive News & Ratings for Abbott Laboratories Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Abbott Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter .

Tags:

Click Here to Continue!


Add a Comment

Your email address will not be published. Required fields are marked *